Toll Free: 1-888-928-9744

Cystic Fibrosis - Pipeline Review, H1 2016

Published: Apr 13, 2016 | Pages: 406 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cystic Fibrosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Cystic Fibrosis - Pipeline Review, H1 2016', provides an overview of the Cystic Fibrosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis
- The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Content
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Cystic Fibrosis Overview 12 Therapeutics Development 13 Pipeline Products for Cystic Fibrosis - Overview 13 Pipeline Products for Cystic Fibrosis - Comparative Analysis 14 Cystic Fibrosis - Therapeutics under Development by Companies 15 Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes 21 Cystic Fibrosis - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Cystic Fibrosis - Products under Development by Companies 26 Cystic Fibrosis - Products under Investigation by Universities/Institutes 34 Cystic Fibrosis - Companies Involved in Therapeutics Development 35 Actelion Ltd 35 Akari Therapeutics, Plc 36 Alaxia SAS 37 AlgiPharma AS 38 AmpliPhi Biosciences Corporation 39 Arcturus Therapeutics, Inc 40 Aridis Pharmaceuticals LLC 41 AstraZeneca Plc 42 Bayer AG 43 Boehringer Ingelheim GmbH 44 Calista Therapeutics, Inc. 45 Carolus Therapeutics, Inc. 46 Celtaxsys, Inc. 47 Chiesi Farmaceutici SpA 48 Cilian AG 49 Concert Pharmaceuticals, Inc. 50 Corbus pharmaceuticals, Inc. 51 CSA Biotechnologies LLC 52 Cyclacel Pharmaceuticals, Inc. 53 DiscoveryBiomed, Inc. 54 Editas Medicine, Inc. 55 Errant Gene Therapeutics, LLC 56 Galapagos NV 57 GlaxoSmithKline Plc 58 Grifols, S.A. 59 Grupo Praxis Pharmaceutical SA 60 Horizon Pharma Plc 61 Insmed Incorporated 62 Invion Limited 63 JHL Biotech, Inc. 64 Kamada Ltd. 65 La Jolla Pharmaceutical Company 66 Lamellar Biomedical Ltd 67 Laurent Pharmaceuticals Inc. 68 Mast Therapeutics, Inc. 69 Merck & Co., Inc. 70 Microbion Corporation 71 Mucokinetica Ltd. 72 NanoBio Corporation 73 Nivalis Therapeutics, Inc. 74 Nostrum Pharmaceuticals, LLC 75 Novabiotics Limited 76 Novartis AG 77 OSE Pharma SA 78 Parion Sciences, Inc. 79 Pfizer Inc. 80 Pharmaxis Limited 81 PhaseBio Pharmaceuticals, Inc. 82 Polyphor Ltd. 83 Progenra, Inc. 84 ProMetic Life Sciences Inc. 85 ProQR Therapeutics N.V. 86 Protalix BioTherapeutics, Inc. 87 Proteostasis Therapeutics, Inc. 88 PTC Therapeutics, Inc. 89 Pulmatrix, Inc. 90 Raptor Pharmaceutical Corp. 91 ReveraGen BioPharma, Inc. 92 Savara Inc. 93 Serendex Pharmaceuticals A/S 94 Shionogi & Co., Ltd. 95 Shire Plc 96 Synovo GmbH 97 TGV-Laboratories 98 The International Biotechnology Center (IBC) Generium 99 Verona Pharma Plc 100 Vertex Pharmaceuticals Incorporated 101 Xenetic Biosciences (UK) Limited 102 Zambon Company S.p.A. 103 Cystic Fibrosis - Therapeutics Assessment 104 Assessment by Monotherapy Products 104 Assessment by Combination Products 105 Assessment by Target 106 Assessment by Mechanism of Action 111 Assessment by Route of Administration 115 Assessment by Molecule Type 117 Drug Profiles 119 (ammonium chloride + citric acid + sodium citrate) - Drug Profile 119 (fosfomycin + tobramycin) - Drug Profile 120 (ivacaftor + tezacaftor) - Drug Profile 121 ABPA-01 - Drug Profile 122 acebilustat - Drug Profile 124 Aerucin - Drug Profile 126 alpha-1 proteinase inhibitor (human) second generation - Drug Profile 127 ALX-009 - Drug Profile 130 amikacin sulphate - Drug Profile 132 amlexanox - Drug Profile 137 Anti-Pseudomonas IgY - Drug Profile 138 Antimicrobial Drug for Cystic Fibrosis - Drug Profile 140 AT-010 - Drug Profile 141 ataluren - Drug Profile 142 AZD-5634 - Drug Profile 146 BI-443651 - Drug Profile 147 Biologics for Cystic Fibrosis Lung Infections - Drug Profile 148 Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile 149 Brevenal - Drug Profile 150 Calcaftor - Drug Profile 151 CFX-1 - Drug Profile 152 CSA-13 - Drug Profile 153 CSY-0073 - Drug Profile 154 CT-2009 - Drug Profile 155 CTP-656 - Drug Profile 156 cysteamine IR - Drug Profile 157 dapsone - Drug Profile 159 Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis - Drug Profile 160 doripenem - Drug Profile 161 dornase alfa biosimilar - Drug Profile 163 dornase alfa biosimilar - Drug Profile 164 Drugs for Cystic Fibrosis - Drug Profile 165 FDL-169 - Drug Profile 166 fenretinide - Drug Profile 167 Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile 168 Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile 170 Gene Therapy to Activate CFTR Gene for Cystic Fibrosis - Drug Profile 171 GLPG-1837 - Drug Profile 172 GLPG-1837 + GLPG-2222 + GLPG-2665 - Drug Profile 174 GLPG-2222 - Drug Profile 175 GLPG-2451 - Drug Profile 176 GLPG-2665 - Drug Profile 177 GLPG-2737 - Drug Profile 178 GLPG-2851 - Drug Profile 179 glycerol phenylbutyrate - Drug Profile 180 GSK-2225745 - Drug Profile 184 itraconazole - Drug Profile 185 JBT-101 - Drug Profile 186 kenpaullone - Drug Profile 188 levofloxacin - Drug Profile 189 levofloxacin - Drug Profile 193 LJPC-30Sa - Drug Profile 194 LJPC-30Sb - Drug Profile 195 LMS-611 - Drug Profile 196 LUNAR-CF - Drug Profile 198 mannitol - Drug Profile 199 MBN-101 - Drug Profile 202 MG-277 - Drug Profile 204 miglustat - Drug Profile 205 MKA-104 - Drug Profile 207 molgramostim - Drug Profile 208 Mul-1867 - Drug Profile 212 N-91115 - Drug Profile 213 N-91138 - Drug Profile 214 N-91169 - Drug Profile 215 nadolol - Drug Profile 216 NB-401 - Drug Profile 219 nitric oxide - Drug Profile 220 nitric oxide - Drug Profile 222 Nu-3 - Drug Profile 223 NVPQBE-170 - Drug Profile 224 Oligomer G for Cystic Fibrosis - Drug Profile 225 ORP-100 - Drug Profile 227 P-1055 - Drug Profile 228 PAC-IC - Drug Profile 229 Panaecin - Drug Profile 230 PB-01 - Drug Profile 231 PB-1046 - Drug Profile 232 PB-1120 - Drug Profile 234 PBI-4050 - Drug Profile 235 POL-6014 - Drug Profile 237 PRX-110 - Drug Profile 239 PTI-130 - Drug Profile 240 PTI-428 - Drug Profile 241 PTIC-1811 - Drug Profile 242 PTIP-271 - Drug Profile 243 PulmoXen - Drug Profile 244 PXS-4728A - Drug Profile 245 QR-010 - Drug Profile 246 QRX-4 - Drug Profile 247 Recombinant A1PI - Drug Profile 248 Recombinant Acid Ceramidase Replacement for Farber Disease and Cystic Fibrosis - Drug Profile 250 Recombinant Enzyme to Target DNA for Cystic Fibrosis - Drug Profile 251 Recombinant Protein for Infectious Diseases and Respiratory Disorders - Drug Profile 252 riociguat - Drug Profile 254 RPL-554 - Drug Profile 256 S-1226 - Drug Profile 259 S-1229 - Drug Profile 261 S-18 - Drug Profile 262 seliciclib - Drug Profile 263 SHP-637 - Drug Profile 265 Small Molecule for Cystic Fibrosis - Drug Profile 266 Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis - Drug Profile 267 Small Molecule to Activate CFTR for Cystic Fibrosis - Drug Profile 268 Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 269 Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD - Drug Profile 270 Small Molecules for Bacterial Infections - Drug Profile 271 Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis - Drug Profile 272 Small Molecules for Cystic Fibrosis - Drug Profile 273 Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile 274 Small Molecules to Activate CFTR Protein for Cystic Fibrosis - Drug Profile 275 Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 276 Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis - Drug Profile 277 Small Molecules to Block SCNN1 for Cystic Fibrosis - Drug Profile 278 Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 279 Small Molecules to Inhibit USP8 for Cystic Fibrosis - Drug Profile 280 sodium nitrite - Drug Profile 281 solithromycin - Drug Profile 283 SP-14 - Drug Profile 286 SP-9 - Drug Profile 287 Stem Cell Therapy for Cystic Fibrosis - Drug Profile 288 SYGN-113 - Drug Profile 289 SYGN-303 - Drug Profile 290 tritoqualine - Drug Profile 291 vamorolone - Drug Profile 292 vancomycin hydrochloride - Drug Profile 294 VX-152 - Drug Profile 296 VX-371 - Drug Profile 297 VX-440 - Drug Profile 298 ZP-046 - Drug Profile 299 Cystic Fibrosis - Recent Pipeline Updates 300 Cystic Fibrosis - Dormant Projects 378 Cystic Fibrosis - Discontinued Products 387 Cystic Fibrosis - Product Development Milestones 388 Featured News & Press Releases 388 Appendix 396 Methodology 396 Coverage 396 Secondary Research 396 Primary Research 396 Expert Panel Validation 396 Contact Us 396 Disclaimer 397
List of Tables
Number of Products under Development for Cystic Fibrosis, H1 2016 22 Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H1 2016 23 Number of Products under Development by Companies, H1 2016 24 Number of Products under Development by Companies, H1 2016 (Contd..1) 25 Number of Products under Development by Companies, H1 2016 (Contd..2) 26 Number of Products under Development by Companies, H1 2016 (Contd..3) 27 Number of Products under Development by Companies, H1 2016 (Contd..4) 28 Number of Products under Development by Companies, H1 2016 (Contd..5) 29 Number of Products under Investigation by Universities/Institutes, H1 2016 30 Comparative Analysis by Late Stage Development, H1 2016 31 Comparative Analysis by Clinical Stage Development, H1 2016 32 Comparative Analysis by Early Stage Development, H1 2016 33 Comparative Analysis by Unknown Stage Development, H1 2016 34 Products under Development by Companies, H1 2016 35 Products under Development by Companies, H1 2016 (Contd..1) 36 Products under Development by Companies, H1 2016 (Contd..2) 37 Products under Development by Companies, H1 2016 (Contd..3) 38 Products under Development by Companies, H1 2016 (Contd..4) 39 Products under Development by Companies, H1 2016 (Contd..5) 40 Products under Development by Companies, H1 2016 (Contd..6) 41 Products under Development by Companies, H1 2016 (Contd..7) 42 Products under Investigation by Universities/Institutes, H1 2016 43 Cystic Fibrosis - Pipeline by Actelion Ltd, H1 2016 44 Cystic Fibrosis - Pipeline by Akari Therapeutics, Plc, H1 2016 45 Cystic Fibrosis - Pipeline by Alaxia SAS, H1 2016 46 Cystic Fibrosis - Pipeline by AlgiPharma AS, H1 2016 47 Cystic Fibrosis - Pipeline by AmpliPhi Biosciences Corporation, H1 2016 48 Cystic Fibrosis - Pipeline by Arcturus Therapeutics, Inc, H1 2016 49 Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 50 Cystic Fibrosis - Pipeline by AstraZeneca Plc, H1 2016 51 Cystic Fibrosis - Pipeline by Bayer AG, H1 2016 52 Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 53 Cystic Fibrosis - Pipeline by Calista Therapeutics, Inc., H1 2016 54 Cystic Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2016 55 Cystic Fibrosis - Pipeline by Celtaxsys, Inc., H1 2016 56 Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H1 2016 57 Cystic Fibrosis - Pipeline by Cilian AG, H1 2016 58 Cystic Fibrosis - Pipeline by Concert Pharmaceuticals, Inc., H1 2016 59 Cystic Fibrosis - Pipeline by Corbus pharmaceuticals, Inc., H1 2016 60 Cystic Fibrosis - Pipeline by CSA Biotechnologies LLC , H1 2016 61 Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 62 Cystic Fibrosis - Pipeline by DiscoveryBiomed, Inc., H1 2016 63 Cystic Fibrosis - Pipeline by Editas Medicine, Inc., H1 2016 64 Cystic Fibrosis - Pipeline by Errant Gene Therapeutics, LLC, H1 2016 65 Cystic Fibrosis - Pipeline by Galapagos NV, H1 2016 66 Cystic Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2016 67 Cystic Fibrosis - Pipeline by Grifols, S.A., H1 2016 68 Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2016 69 Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H1 2016 70 Cystic Fibrosis - Pipeline by Insmed Incorporated, H1 2016 71 Cystic Fibrosis - Pipeline by Invion Limited, H1 2016 72 Cystic Fibrosis - Pipeline by JHL Biotech, Inc., H1 2016 73 Cystic Fibrosis - Pipeline by Kamada Ltd., H1 2016 74 Cystic Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H1 2016 75 Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H1 2016 76 Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc., H1 2016 77 Cystic Fibrosis - Pipeline by Mast Therapeutics, Inc., H1 2016 78 Cystic Fibrosis - Pipeline by Merck & Co., Inc., H1 2016 79 Cystic Fibrosis - Pipeline by Microbion Corporation, H1 2016 80 Cystic Fibrosis - Pipeline by Mucokinetica Ltd., H1 2016 81 Cystic Fibrosis - Pipeline by NanoBio Corporation, H1 2016 82 Cystic Fibrosis - Pipeline by Nivalis Therapeutics, Inc., H1 2016 83 Cystic Fibrosis - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2016 84 Cystic Fibrosis - Pipeline by Novabiotics Limited, H1 2016 85 Cystic Fibrosis - Pipeline by Novartis AG, H1 2016 86 Cystic Fibrosis - Pipeline by OSE Pharma SA, H1 2016 87 Cystic Fibrosis - Pipeline by Parion Sciences, Inc., H1 2016 88 Cystic Fibrosis - Pipeline by Pfizer Inc., H1 2016 89 Cystic Fibrosis - Pipeline by Pharmaxis Limited, H1 2016 90 Cystic Fibrosis - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 91 Cystic Fibrosis - Pipeline by Polyphor Ltd., H1 2016 92 Cystic Fibrosis - Pipeline by Progenra, Inc., H1 2016 93 Cystic Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2016 94 Cystic Fibrosis - Pipeline by ProQR Therapeutics N.V., H1 2016 95 Cystic Fibrosis - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 96 Cystic Fibrosis - Pipeline by Proteostasis Therapeutics, Inc., H1 2016 97 Cystic Fibrosis - Pipeline by PTC Therapeutics, Inc., H1 2016 98 Cystic Fibrosis - Pipeline by Pulmatrix, Inc., H1 2016 99 Cystic Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H1 2016 100 Cystic Fibrosis - Pipeline by ReveraGen BioPharma, Inc., H1 2016 101 Cystic Fibrosis - Pipeline by Savara Inc., H1 2016 102 Cystic Fibrosis - Pipeline by Serendex Pharmaceuticals A/S, H1 2016 103 Cystic Fibrosis - Pipeline by Shionogi & Co., Ltd., H1 2016 104 Cystic Fibrosis - Pipeline by Shire Plc, H1 2016 105 Cystic Fibrosis - Pipeline by Synovo GmbH, H1 2016 106 Cystic Fibrosis - Pipeline by TGV-Laboratories, H1 2016 107 Cystic Fibrosis - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 108 Cystic Fibrosis - Pipeline by Verona Pharma Plc, H1 2016 109 Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 110 Cystic Fibrosis - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 111 Cystic Fibrosis - Pipeline by Zambon Company S.p.A., H1 2016 112 Assessment by Monotherapy Products, H1 2016 113 Assessment by Combination Products, H1 2016 114 Number of Products by Stage and Target, H1 2016 116 Number of Products by Stage and Mechanism of Action, H1 2016 121 Number of Products by Stage and Route of Administration, H1 2016 125 Number of Products by Stage and Molecule Type, H1 2016 127 Cystic Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016 309 Cystic Fibrosis - Dormant Projects, H1 2016 387 Cystic Fibrosis - Dormant Projects (Contd..1), H1 2016 388 Cystic Fibrosis - Dormant Projects (Contd..2), H1 2016 389 Cystic Fibrosis - Dormant Projects (Contd..3), H1 2016 390 Cystic Fibrosis - Dormant Projects (Contd..4), H1 2016 391 Cystic Fibrosis - Dormant Projects (Contd..5), H1 2016 392 Cystic Fibrosis - Dormant Projects (Contd..6), H1 2016 393 Cystic Fibrosis - Dormant Projects (Contd..7), H1 2016 394 Cystic Fibrosis - Dormant Projects (Contd..8), H1 2016 395 Cystic Fibrosis - Discontinued Products, H1 2016 396


List of Figures
Number of Products under Development for Cystic Fibrosis, H1 2016 22 Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H1 2016 23 Number of Products under Development by Companies, H1 2016 24 Number of Products under Investigation by Universities/Institutes, H1 2016 30 Comparative Analysis by Late Stage Development, H1 2016 31 Comparative Analysis by Clinical Stage Development, H1 2016 32 Comparative Analysis by Early Stage Products, H1 2016 33 Assessment by Monotherapy Products, H1 2016 113 Assessment by Combination Products, H1 2016 114 Number of Products by Top 10 Targets, H1 2016 115 Number of Products by Stage and Top 10 Targets, H1 2016 115 Number of Products by Top 10 Mechanism of Actions, H1 2016 120 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 120 Number of Products by Routes of Administration, H1 2016 124 Number of Products by Stage and Routes of Administration, H1 2016 124 Number of Products by Top 10 Molecule Types, H1 2016 126 Number of Products by Stage and Top 10 Molecule Types, H1 2016 126

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify